• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » BioNano Genomics launches Irys for complex human genome analysis

BioNano Genomics launches Irys for complex human genome analysis

November 7, 2012
CenterWatch Staff

BioNano Genomics, a San Diego-based genomics company, has launched its Irys System, an intuitively designed genome mapping system that empowers genomics researchers with a new way of analyzing genomic DNA.

Irys System makes it possible to routinely and accurately detect genomic structural variation and to finish genome assemblies. It reveals genome architecture in its native state, thereby adding a completely new repertoire to the genomics tool kit.

“The Irys System allows researchers and clinicians to access meaningful biological information that is disrupted or completely lost when samples are analyzed by the methods used today such as next-generation sequencing or microarrays,” said Dr. R. Erik Holmlin, president and CEO of BioNano Genomics. “BioNano Genomics is excited about introducing a new approach that makes it easy to observe genomic architecture and context. We believe this capability will add unprecedented insight into biology and usher in a new wave of discoveries.”

The fully automated Irys benchtop instrument uses the IrysChip to uncoil and confine long DNA molecules in proprietary Nanochannel Arrays where they are uniformly linearized in a highly parallel display for high-resolution, single-molecule imaging. Irys does not employ DNA fragmentation or amplification, which are typical with next-generation sequencing. The result is sequence information over extremely long “reads” ranging from hundreds of kilobases to a megabase, where the sample’s valuable structural information is preserved. Irys makes it possible for researchers to directly observe structural variants including replications, deletions, translocations and inversions.

“The simplicity, affordability and speed of Irys, which can analyze several gigabases per hour, make it an ideal genome mapping solution for labs of any size,” said Todd Dickinson, vice president of commercial operations, BioNano Genomics. “We envision broad application throughout genomics and epigenomics, especially in biomedical research and ultimately molecular diagnostics.”

Pui-Yan Kwok, MD, PhD, the Henry Bachrach Distinguished Professor at the University of California, San Francisco School of Medicine, was the senior author of a study published in Nature Biotechnology, which demonstrated the utility of the Irys platform for structural variation analysis and de novo assembly of next generation sequencing (NGS) data.

“Complex genomes contain highly repetitive sequences and prove challenging for whole genome assembly,” said Kwok. “The BioNano approach to genome mapping readily handled these issues, and allowed us to achieve haplotype-resolved de novo assembly of the notoriously difficult human MHC region. We are thrilled with the quality of data we are getting with the Irys system and are now deploying this new technology broadly across our research program.”

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing